Citigroup - Mylan "buy"

Mylan 21,15 € +2,27% ,GrB  

328.911 sind bereits durch ,buran und danke und weitermachen  

Handelsplatz Geld-Stk. Geld Geld-Brief Brief Brief-Stk. Spread  Zeit
Tradegate  300 20,88 €    21,13 € 300 1,20%  10:36:16  
Berlin  300 20,88 €    21,13 € 300 1,20%  10:36:16  
Düsseldorf  0 20,87 €    21,145 € 0 1,32%  10:36:19  
Frankfurt  480 20,868 €    21,144 € 473 1,32%  10:36:16  
München  200 20,865 €    21,145 € 200 1,34%  10:36:16  
Stuttgart  1.000 20,70 €    21,215 € 1.000 2,49%  10:31:39  
Nasdaq  400 27,21 $    30,55 $ 200 12,27%  10:02:01  
GrB  

Kaufpreis 28,49 $ ..600 shares ..spread 2,04%  

Handelsplatz Geld-Stk. Geld Geld-Brief Brief Brief-Stk. Spread  Zeit
Tradegate  300 20,85 €    21,09 € 300 1,15%  11:20:59  
Berlin  300 20,88 €     21,12 € 300 1,15%  11:05:59  
Frankfurt  480 20,866 €    21,13 € 474 1,27%  11:07:59  
Düsseldorf  0 20,865 €    21,13 € 0 1,27%  11:08:02  
München  200 20,865 €    21,13 € 200 1,27%  11:05:59  
Stuttgart  1.000 20,66 €    21,175 € 1.000 2,49%  10:56:40  
Nasdaq  200 27,21 $    28,45 $ 100 4,56%  11:08:02  
GrB  

2.926.516 shares unter'm Ticker geschmissen und bedient  

Datum Erster Hoch Tief Schluss     Stücke Volumen
22.01.13 27,97 28,00 27,74  27,89 $ 3.906.444 107 M
GrB  

http://www.ariva.de/news/...teen-National-Scholarship-Winners-4413119 GrB  

http://www.ariva.de/news/C-O-R-R-E-C-T-I-O-N-Mylan-Inc-4415055 GrB  

Zeit  Kurs  Stück  
08:02:27 21,30 €  500  

bei nem starken Volumen von 81,6 M ..Schluss in zart rosa ..geht voll klar  

Euro: 20,991 €
buran  

Datum Erster Hoch Tief Schluss     Stücke Volumen
29.01.13 28,25 28,385 28,11  28,29 $ 3.998.319 105 M
GrB  

557.309 Stücke bedient ,GrB  

gutes Blatt

Datum Erster Hoch Tief Schluss     Stücke Volumen
30.01.13 28,26 28,42 28,12  28,20 $ 4.323.323 114 M

thread Pott +188,46%  

http://www.ariva.de/news/...tially-Life-Threatening-Allergies-4421914 GrB

...........+0,39% realtime  

Datum Erster Hoch Tief Schluss     Stücke Volumen
31.01.13 28,15 28,40 28,06  28,27 $ 6.128.407 172 M  

ask:: Preis:: 31,21 $ shares:: 200 spread:: 8,71% / buran  

1.769.977 shares getickert .. 29,04 in Dollar waren bereits zu sehen / buran  

ohne Makel und Einwände

Schlusswerte::28,86 $ +0,20% +0,06 $ In Euro: 21,594 € | Nasdaq buran  

http://www.ariva.de/news/...Rajiv-Malik-to-Board-of-Directors-4432023 GrB  

Mylan 21,66 € +0,77%
__________________
undddd Abfahrt ,buran  

http://www.ariva.de/news/...rth-Quarter-and-Year-End-2012-Fin-4435110 GrB  

Mylan Launches Generic Version of Xopenex® Inhalation Solution16:05 18.03.13


PR Newswire

PITTSBURGH, March 18, 2013

PITTSBURGH, March 18, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate). This product is the generic version of Sunovion's Xopenex® Inhalation Solution, which is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.

Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL, 0.63 mg/3 mL, and 1.25 mg/3 mL, had U.S. sales of approximately $438.8 million for the 12 months ending Dec. 31, 2012, according to IMS Health. Mylan has begun shipping this product.

Currently, Mylan has 182 ANDAs pending FDA approval representing $80 billion in annual sales, according to IMS Health. Thirty-six of these pending ANDAs are potential first-to-file opportunities, representing $21.1 billion in annual brand sales, for the 12 months ending June 30, 2012, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.


Quelle: PR Newswire

GrB  

Bucheinsicht:

Zeit  Kurs  Stück  
11:29:10 22,615 €  15

MfG b.